The Asia-Pacific region has seen a 39% increase in the number of immunology trials taking place over the past decade, the largest increase for any region worldwide.
The region ranks in first for the percentage growth in trials taking place, compared to its sixth-placed ranking in 2010.
These figures come from GlobalData’s extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.
The Asia-Pacific region saw the biggest increase in immunology related trials.
Between 2010 and 2020, there was a 39% increase in the number of trials taking place.
In 2020, the largest proportion of trials in the region took place in China with 43.5% of all trials in the region taking place there.
Japan and India had the next largest percentage of trials taking place in the region with 13.7% and 10.2%, respectively.
Africa saw a 18% decrease in the number of immunology trials taking place.
South Africa saw the largest amount of trials taking place, in 2020, at 48.1%.
Trials in Egypt and Mauritius also made up a large proportion of the trials taking place with 44.4% and 3.7%, respectively.
The Middle East saw a 19% decrease in the number trials taking place.
Iran, Israel and Saudi Arabia made up the most trials in the region, with 41%, 35.9% and 12.8%, respectively.
North America saw a 24% decrease in immunology related trials taking place.
The United States saw the largest percentage of trials taking place in the region at 77.1%.
Canada and Mexico also made up a significant proportion of the trials taking place.
South and Central America
South and Central America saw a decrease in the number of immunology trials.
The region saw a 28% decrease in the number of trials.
Argentina made up 26.8% the largest proportion of trials taking place in the region.
Brazil and Chile also made up a large amount of the trials taking place with 23.9% and 15.5%, respectively.
Europe saw the biggest decrease in immunology trials.
The number of trials in the region fell by 31% between 2010 and 2020.
Germany saw the largest percentage of trials taking place in the region with 11.1%.